Navigation Links
Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001

roduced at this year's congress of the American Society for Clinical Oncology (ASCO) in Chicago, USA. VPM globally has a number of exclusive licenses for promising vaccines, with a group of other projects in the pipeline. VPM4001 has been licensed from Sloan Kettering Institute for Cancer Research, New York. VPM's products are developed in cooperation with experienced partner companies which provide the required technological and scientific expertise. This allows for the more rapid and more successful international development of products.

Vakzine Projekt Management GmbH

VPM (Vakzine Projekt Management GmbH, Hanover, Germany, www.vakzine-manager.de) develops vaccines and biopharmaceuticals. VPM is funded by the German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF).

About American Society for Clinical Oncology (ASCO)

www.asco.org

Contact

Vakzine Projekt Management GmbH
Dr. Albrecht Läufer, +49 (511) 16 99 08 10
Fax: +49 (511) 16 99 08 29
laeufer@vakzine-manager.de
www.vakzine-manager.de


'"/>




Page: 1 2

Related medicine technology :

1. Choosing Lab Quality Management Software
2. Optimizing Quality Control Data Management
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
(Date:9/3/2008)...follow up results from chronically infected Hepati...e data obtained earlier in 2008, - Study is the ...-term antiviral effect of therapeutic Hepat...ngly support move into a second generation, vacci...ting through TLR act...
(Date:9/3/2008)..., Md., Sept. 3 /- Panacea Pharmaceuti...tent Number 7,413,737 covering,antibodies against ...H), a,proprietary human cancer biomarker and thera...collaboration with the Massachusetts Institute of,...ide rights to this patent,for development of human...
(Date:9/3/2008)...ses Operations, Updates Zingo Launch Progress and ...y Conference Call Today at 11:30 ...wswire-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ...e,operations to focus on commercial and late-stage...to a specialty pharmaceutical pain management,comp...
(Date:9/3/2008)...any, Sept. 3 /- A sub-analy...at treatment with prasugrel,compared with clopidog...rent heart attacks (7.4 percent vs. 9.7 percent, p...d around the time of an artery-opening,procedure k...or if they,occurred spontaneously during the longe...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 1Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 2Laser Energetics Files Patent Application for a New BrightStar 28TM 29 Alexandrite Laser 16678 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 1Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4567 4Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 1Perrigo Announces Approval for Over the Counter Childrens Cetirizine Oral Solution 1763 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 1Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 3Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 4
...007 - CytRx Corporation,(NASDAQ:CYTR), a biopharma...mmercialization of human therapeutics, today,annou... extension,of its completed Phase IIa clinical tri...linical trial was not placebo-controlled,arimoclo... be safe,and well-tolerated throughout the six-mon...
...ganon, the human,healthcare business unit of Akzo ... III clinical trials with corifollitropin alfa,(Or...e reached,their randomization target. , ,Corifoll...e. It is,the first of a new class of gonadotropins...h, due to its long half-life, one single,injection...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:9/5/2008)...are enhanced by taking into account risk factors b...ding to research teams led by epidemiologists at T...r in two complementary papers appearing in the Sep...In the first study to focus on African-Americans, ...d exposure to certain risks. Based upon these find...
(Date:9/4/2008)...ed to physicians by pharmaceutical companies could...e long run, according to a study done by researche...r and colleagues. , The retrospective study look...cians in a university-affiliated internal medicine...er the closing of their drug sample closet. The re...
(Date:9/4/2008)...shortchanging their golden years by tapping into S... of Illinois expert who has studied the federal re...than three of every four Americans trim their mont...nefits early, a choice many might forego if they b...ences, law professor Richard L. Kaplan says. , A...
(Date:9/4/2008)...nfection risk , , THURSDAY, Sept. 4 (He...sked the manufacturers of four widely used immunos... risk of developing opportunistic fungal infection...cade, belong to a class of medications known as tu...kers), which suppress the immune system and are ap...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...ing themselves in a tight corner with finances bei... seek for further Medicaid cuts. The physician acr... in dire consequences for patient care. To add to...cut off $3 billion from the Medicaid program, and ...
...velopment of cancer. Cells without this protein ar...ability would either kill a cell or keep it from g... such a way that they are able to multiply creatin... itself doesn't cause cancer but its absence gives...
...hy women may sometimes be caused by the presence o... after a previous abortion. There were evidence ov...behind after abortion cause chronic irritation whi...octors at the University of Ottawa found that in s...
...ng loss in older people and have found that 25 to ...impaired. Doctors while examining older patients m... remedied. The condition can lead to depression, s...y. There are several reliable tests to detect hear...
Other Medicine News:
Catheters are available in two tip styles- the smooth, atraumatic DeLee tip with staggered eyes, and the angled Whistle tip. Two types of catheter valve options, SAFE-T-VAC and TOUCH-TROL, deliver ea
Sterile Straight Packed TOUCH-TROL Suction Catheters
Tracheal Suction Latex Rubber Catheters - Funnel End
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation.
Medicine Products: